As of Sep 02
| +0.92 / +4.89%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 23.50, with a high estimate of 35.00 and a low estimate of 20.00. The median estimate represents a +18.99% increase from the last price of 19.75.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.